TY - JOUR
T1 - IMiDs induce FAM83F degradation via an interaction with CK1α to attenuate Wnt signalling
AU - Dunbar, Karen
AU - Macartney, Thomas J.
AU - Sapkota, Gopal
N1 - Funding Information:
We thank E Allen, L Fin, J Stark, and A Muir for help and assistance with tissue culture, the staff at the DNA sequencing service (School of Life Sciences, University of Dundee), the cloning, antibody, and protein production teams within the Medical Research Council-Protein Phosphorylation and Ubiq-uitylation Unit (MRC-PPU) reagents and services (University of Dundee) coordinated by J Hastie and Natalia Shpiro (MRC-PPU) for synthesis of BTX161. We thank the staff at the Dundee Imaging Facility (School of Life Sciences, University of Dundee) and the Flow Cytometry Facility (School of Life Sciences, University of Dundee) for their invaluable help and advice throughout this project. We thank all members of the Sapkota lab for their highly appreciated experimental advice and/or discussions. Funding: K Dunbar is supported by an MRC Career Development Fellowship. GP Sapkota is supported by the UK Medical Research Council (grant numbers MC_UU_00018/6 and MC_UU_12016/3) and the pharmaceutical companies supporting the Division of Signal Transduction Therapy (DSTT) (Boehringer-Ingelheim, GlaxoSmithKline, Merck-Serono).
Publisher Copyright:
© This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/2
Y1 - 2021/2
N2 - Immunomodulatory imide drugs (IMiDs) bind CRBN, a substrate receptor of the Cul4A E3 ligase complex, enabling the recruitment of neo-substrates, such as CK1α, and their degradation via the ubiquitin-proteasome system. Here, we report FAM83F as such a neosubstrate. The eight FAM83 proteins (A-H) interact with and regulate the subcellular distribution of CK1α. We demonstrate that IMiD-induced FAM83F degradation requires its association with CK1α. However, no other FAM83 protein is degraded by IMiDs. We have recently identified FAM83F as a mediator of the canonical Wnt signalling pathway. The IMiDinduced degradation of FAM83F attenuated Wnt signalling in colorectal cancer cells and removed CK1α from the plasma membrane, mirroring the phenotypes observed with genetic ablation of FAM83F. Intriguingly, the expression of FAM83G, which also binds to CK1α, appears to attenuate the IMiD-induced degradation of CK1α, suggesting a protective role for FAM83G on CK1α. Our findings reveal that the efficiency and extent of target protein degradation by IMiDs depends on the nature of inherent multiprotein complex in which the target protein is part of.
AB - Immunomodulatory imide drugs (IMiDs) bind CRBN, a substrate receptor of the Cul4A E3 ligase complex, enabling the recruitment of neo-substrates, such as CK1α, and their degradation via the ubiquitin-proteasome system. Here, we report FAM83F as such a neosubstrate. The eight FAM83 proteins (A-H) interact with and regulate the subcellular distribution of CK1α. We demonstrate that IMiD-induced FAM83F degradation requires its association with CK1α. However, no other FAM83 protein is degraded by IMiDs. We have recently identified FAM83F as a mediator of the canonical Wnt signalling pathway. The IMiDinduced degradation of FAM83F attenuated Wnt signalling in colorectal cancer cells and removed CK1α from the plasma membrane, mirroring the phenotypes observed with genetic ablation of FAM83F. Intriguingly, the expression of FAM83G, which also binds to CK1α, appears to attenuate the IMiD-induced degradation of CK1α, suggesting a protective role for FAM83G on CK1α. Our findings reveal that the efficiency and extent of target protein degradation by IMiDs depends on the nature of inherent multiprotein complex in which the target protein is part of.
KW - Lenalidomide
KW - Pomalidomide
KW - BTX161
KW - Cereblon
KW - Colorectal cancer
UR - http://www.scopus.com/inward/record.url?scp=85099075628&partnerID=8YFLogxK
U2 - 10.26508/lsa.202000804
DO - 10.26508/lsa.202000804
M3 - Article
C2 - 33361334
SN - 2575-1077
VL - 4
JO - Life Science Alliance
JF - Life Science Alliance
IS - 2
M1 - e202000804
ER -